PTAB Won't Sanction Bass For AIA Reviews Of Drug Patents

Law360, New York (September 25, 2015, 10:44 PM EDT) -- The Patent Trial and Appeal Board refused Friday to sanction hedge fund manager Kyle Bass at the request of Celgene Corp. after the company argued that Bass is abusing the inter partes review process, saying there is nothing wrong with what Bass is doing.

Celgene argued to the board that Bass’ Coalition for Affordable Drugs is challenging patents as part of a short-selling strategy designed to make money by driving down the price of Celgene's stock, but the PTAB declined to grant the requested relief, saying “profit is at the heart of nearly every patent and nearly every inter partes review.”...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS